In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Commentary|Articles|June 18, 2026
ASCO 2026 Breast Cancer Trials Affirm De-Escalation, Earlier Switching
Author(s)Coral O. Omene, MD, PhD, Sabrina Serani
ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.
Advertisement
Advertisement
Several trials presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting reinforced a multiyear push toward de-escalating and individualizing breast cancer treatment, according to Coral Omene, MD, PhD, program director of Breast Cancer Disparities Research and a medical oncologist at Rutgers Cancer Institute, and associate professor of medicine at Rutgers Robert Wood Johnson Medical School.
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
Advertisement
Advertisement